Kaitlyn Arsenault - Oct 4, 2021 Form 4 Insider Report for Skye Bioscience, Inc. (SKYE)

Role
Chief Financial Officer
Signature
Kaitlyn Arsenault
Stock symbol
SKYE
Transactions as of
Oct 4, 2021
Transactions value $
$0
Form type
4
Date filed
10/5/2021, 08:42 PM
Next filing
Dec 16, 2021

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SKYE Employee Stock Option (Right to Buy) Award $0 +1.6M +400% $0.00 2M Oct 4, 2021 Common Stock 1.6M $0.09 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 10% of the Options shall vest on October 4, 2021 (the "Vesting Start Date") and the remaining 90% of the Options will vest in equal semi-annual installments over four annual periods.